Venous Leg Ulcers (VLUs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Venous Leg Ulcers (VLUs) Market Outlook

Thelansis’s “Venous Leg Ulcers (VLUs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Venous Leg Ulcers (VLUs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Venous Leg Ulcers (VLUs) Overview

Venous leg ulcers (VLUs) result from chronic venous insufficiency (CVI) and venous hypertension, typically appearing in later stages. Under normal circumstances, the contraction of calf muscles and functioning intraluminal valves encourage forward blood flow while preventing backflow. However, when retrograde flow or obstructions occur, chronic venous hypertension develops, leading to dermatologic and vascular complications that eventually lead to VLU formation. Although CVI is a well-recognized cause of VLU development, ulceration occurs infrequently (5.1%), and the reasons behind this are not entirely clear. CVI may arise from blood reflux, obstruction, or both, disrupting macro- and micro-circulatory functions. This heightened intraluminal pressure results in the leakage of proteins and the creation of fibrin cuffs, hindering the diffusion of oxygen and growth factors and triggering an inflammatory response. At the cellular level, vein wall remodeling, and varix formation involve mast cell degranulation, recruitment of leukocytes, increased presence of matrix metalloproteinase inhibitors and prostacyclin, transformation of smooth muscle cells into a non-contractile secretory phenotype, and differentiation of fibroblasts into myofibroblasts. The inflammatory environment is sustained mainly by M1 macrophages, which release IL-1α, IFN-γ, and TGF-β1. Ultimately, this sequence of chronic inflammation and compromised blood flow contributes to blood clots forming, further exacerbating fibrosis and damage to valves. This cascade of inflammatory events impairs the natural healing process, leading to the development of ulcers when injuries occur. Most risk factors for VLU development cannot be altered, and patients often have multiple factors. These include a family history of CVI, older age, female gender, previous thrombosis or pulmonary embolism, multiple pregnancies, lipodermatosclerosis, and musculoskeletal and joint disorders. Modifiable risk factors such as obesity and a sedentary lifestyle also affect venous disease. The established treatment approach for VLUs involves two main strategies: compression therapy and direct wound care. Effectively reducing leg edema is crucial for successful wound closure. Various conservative options address venous hypertension, including medical, intermittent pneumatic compression (IPC), manual lymphatic drainage, and extracorporeal shockwave therapy. For VLUs that are less than a year old and smaller than 10 cm2 upon initial assessment, the likelihood of failing to close within six months stands at 29%. This probability rises to 78% for wounds over a year old and larger than 10 cm2. Additional risk factors associated with poor healing include older age, non-white ethnicity, high body mass index, impaired calf muscle pump function, venous reflux, thrombosis, deep vein involvement, and insufficient high-level compression.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Venous Leg Ulcers (VLUs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034